HIV Infections Clinical Trial
Official title:
Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV)
The Lung HIV goal is to facilitate the data and specimen collection efforts of eight individual HIV and pulmonary studies that operate under the direction of the NHLBI. The Lung HIV study will build on existing studies to facilitate the start-up of new projects to further the understanding of the relationship between pulmonary disease and HIV infection. There is only one clinical trial being performed in this network at Ohio State University and it will be reported here.
The Ohio State University Clinical Research Center (CRC), Patient Selection
Study Intervention Subjects:
365 HIV+ male and female smokers will be enrolled to the study and will be recruited over a
two - four year period.
Inclusion criteria
1. 18 years of age and older
2. Diagnosis of HIV (Since the vast majority of our subjects will be recruited through the
OSU Infectious disease clinics and HIV clinical research unit documentation of HIV
status will not be a problem)
3. Self-reported smoking (≥ 5 cigarettes per day to avoid inclusion of occasional,
'social' users and 'chippers');
4. Able and willing to provide informed written consent.
Exclusion criteria:
1. Inability to provide informed consent
2. Inability to understand spoken English
3. Currently diagnosed interstitial lung disease (i.e. sarcoidosis, idiopathic pulmonary
fibrosis) or lung cancer.
Control Subjects Group A:
We will utilize normal subjects for the control study for the Diffusion Capacity of Lung for
Carbon Monoxide (DLCO) and Diffusion capacity of Lung for Nitric Oxide (DLNO), recruited
from the general population. We will recruit 5 males and 5 females in each decade of life
from 21-30, 31-40, 41-50, 51-60, 61-70 (TOTAL= 50 subjects).
Inclusion criteria
1. 21-70 years of age and older
2. HIV Seronegative
3. Able and willing to provide informed written consent.
Exclusion criteria:
1. Inability to provide informed consent
2. Inability to understand spoken English
3. Current smoker or have smoked in the last 10 years or have a > 10 pack year history of
smoking.
4. Currently diagnosed interstitial lung disease (i.e. sarcoidosis, idiopathic pulmonary
fibrosis) or lung cancer.
Control Subjects Group B:
We will utilize normal subjects for the control study for DLCO and DLNO, recruited from the
general population. We will recruit 5 males and 5 females in each decade of life from 21-30,
31-40, 41-50, 51-60, 61-70 (TOTAL= 50 subjects).
Inclusion criteria
1. 21-70 years of age and older
2. HIV Seronegative
3. Current or former smoker with at least a 5 pack year history of smoking
4. Able and willing to provide informed written consent.
Exclusion criteria:
1. Inability to provide informed consent
2. Inability to understand spoken English
3. Currently diagnosed interstitial lung disease (i.e. sarcoidosis, idiopathic pulmonary
fibrosis) or lung cancer.
;
Intervention Model: Single Group Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |